SUBSCRIBE
SUBSCRIBE
News   FDA

FDA Panel to Meet August 13 on Amgen’s Denosumab Drug

June 23, 2009 | 
1 min read

Bookmark and Share

Reuters -- A U.S. advisory panel will discuss Amgen Inc’s experimental osteoporosis drug denosumab at a meeting on Aug. 13, the Food and Drug Administration said on Monday.

FDA Approvals Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Cancer
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
March 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Roche's tower in Shanghai, China
Approvals
Roche Continues Regulatory Run With Acute Stroke Expansion for Heart Attack Drug
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie